转移性软组织肉瘤患者瘤内注射Toll样受体4激动剂联合放疗:1期非随机对照试验
这项1期非随机对照试验在单个学术性肉瘤专科中心纳入12例有可注射病灶的转移性软组织肉瘤患者,评估瘤内注射Toll样受体4激动剂GLA-SE(5 μg和10 μg,每周8次)联合放疗的安全性和疗效。瘤内GLA-SE耐受良好,仅1例(8%)发生2级不良事件,所有患者注射病灶均获局部控制,1例完全消退。作者认为该联合方案耐受良好且局部控制较单纯放疗更持久,但需进一步研究。
要点
- 瘤内GLA-SE联合放疗耐受良好,仅1例(8%)发生2级不良事件。
- 所有患者注射病灶均获局部控制,1例完全消退,平均消退-25%(范围-100%至4%)。
- 局部持久缓解者瘤内T细胞克隆扩增,外周血可见匹配扩增的克隆。
核心结论
- 在这项非随机对照试验中,瘤内GLA-SE联合放疗耐受良好,且局部控制比单纯放疗更持久。
- 局部持久缓解的患者显示瘤内T细胞克隆扩增增强,这些克隆在外周血中也有匹配扩增。
- 有必要进一步研究瘤内GLA-SE与放疗及全身免疫调节的协同作用。
研究设计与样本
- 1期非随机对照试验,在单个学术性肉瘤专科中心进行,时间为2014年11月17日至2016年3月16日,数据分析时间为2016年8月至2022年9月。
- 纳入12例有可注射病灶的转移性软组织肉瘤患者,中位年龄65岁(范围34-78岁),女性8例(67%)。
- 测试两种剂量的瘤内GLA-SE(5 μg和10 μg,每周8次)联合注射病灶放疗的安全性。
- 主要终点为安全性和耐受性;次要和探索性终点包括局部缓解率以及通过免疫组化和T细胞受体测序检测抗肿瘤免疫。
主要发现
- 瘤内GLA-SE耐受良好,仅1例患者(8%)发生2级不良事件。
- 所有患者在8次给药后均达到注射病灶的局部控制,1例患者完全消退(平均消退-25%;范围-100%至4%)。
- 在局部持久缓解的患者中,可检测到肿瘤浸润淋巴细胞增加。
- 1例患者(随访259天时靶病灶-39%)的T细胞受体测序显示原有和新出现的克隆型扩增,多个重排编码相同结合序列汇聚,提示针对抗肿瘤靶点的克隆汇聚。
- 单细胞测序在治疗后外周血中鉴定出相同的扩增T细胞受体克隆,这些T细胞Tbet表达显著增强,提示TH1表型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE) has been studied as immunotherapy in other contexts. OBJECTIVE: To evaluate the safety, efficacy, and immunomodulatory effects of IT GLA-SE with concurrent radiotherapy in patients with metastatic STS with injectable lesions. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 nonrandomized controlled trial of patients with STS was performed at a single academic sarcoma specialty center from November 17, 2014, to March 16, 2016. Data analysis was performed from August 2016 to September 2022. INTERVENTIONS: Two doses of IT GLA-SE (5 μg and 10 μg for 8 weekly doses) were tested for safety in combination with concurrent radiotherapy of the injected lesion. MAIN OUTCOMES AND MEASURES: Primary end points were safety and tolerability. Secondary and exploratory end points included local response rates as well as measurement of antitumor immunity with immunohistochemistry and T-cell receptor (TCR) sequencing of tumor-infiltrating and circulating lymphocytes. RESULTS: Twelve patients (median [range] age, 65 [34-78] years; 8 [67%] female) were treated across the 2 dose cohorts. Intratumoral GLA-SE was well tolerated, with only 1 patient (8%) experiencing a grade 2 adverse event. All patients achieved local control of the injected lesion after 8 doses, with 1 patient having complete regression (mean regression, -25%; range, -100% to 4%). In patients with durable local response, there were detectable increases in tumor-infiltrating lymphocytes. In 1 patient (target lesion -39% at 259 days of follow-up), TCR sequencing revealed expansion of preexisting and de novo clonotypes, with convergence of numerous rearrangements coding for the same binding sequence (suggestive of clonal convergence to antitumor targets). Single-cell sequencing identified these same expanded TCR clones in peripheral blood after treatment; these T cells had markedly enhanced Tbet expression, suggesting TH1 phenotype. CONCLUSIONS AND RELEVANCE: In this nonrandomized controlled trial, IT GLA-SE with concurrent radiotherapy was well tolerated and provided more durable local control than radiotherapy alone. Patients with durable local response demonstrated enhanced IT T-cell clonal expansion, with matched expansion of these clonotypes in the circulation. Additional studies evaluating synergism of IT GLA-SE and radiotherapy with systemic immune modulation are warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02180698.
引用
- Seo YD, Lu H, Black G, et al. Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial. JAMA Oncol. 2023. PMID: 37824131. doi:10.1001/jamaoncol.2023.4015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。